Docetaxel/trastuzumab regime: Uses in HER2-positive early breast cancer

被引：0
|
作者：
Arnheim, Katharina
机构：
来源：
BREAST CARE | 2006年 / 1卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：A1 / A4
页数：4
相关论文
共 50 条
  • [21] Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer
    Sonnenblick, Amir
    Salmon-Divon, Mali
    Salgado, Roberto
    Ponde, Noam
    Loibl, Sibylle
    Denkert, Carsten
    Joensuu, Heikki
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Azaria, Amos
    Loi, Sherene
    Michiels, Stefan
    Sotiriou, Christos
    CANCER RESEARCH, 2020, 80 (04)
  • [22] Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer
    Sonnenblick, Amir
    Salmon-Divon, Mali
    Salgado, Roberto
    Dvash, Efrat
    Ponde, Noam
    Zahavi, Tamar
    Salmon, Asher
    Loibl, Sibylle
    Denkert, Carsten
    Joensuu, Heikki
    Ameye, Lieveke
    Van den Eynden, Gert
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Azaria, Amos
    Loi, Sherene
    Michiels, Stefan
    Richard, Francois
    Sotiriou, Christos
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (01) : 266 - 276
  • [23] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Yamshiro, Hiroyasu
    Iwata, Hiroji
    Masuda, Norikazu
    Yamamoto, Naohito
    Nishimura, Reiki
    Ohtani, Shoichiro
    Sato, Nobuki
    Takahashi, Masato
    Kamio, Takako
    Yamazaki, Kosuke
    Saito, Tsuyoshi
    Kato, Makoto
    Lee, Tecchuu
    Ohno, Shinji
    Kuroi, Katsumasa
    Takano, Toshimi
    Takada, Masahiro
    Yasuno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 709 - 722
  • [24] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 709 - 722
  • [25] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [26] HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon’s Perspective
    Swati Kulkarni
    David G. Hicks
    Annals of Surgical Oncology, 2008, 15 : 1677 - 1688
  • [27] HER2-Positive early breast cancer and trastuzumab: A surgeon's perspective
    Kulkarni, Swati
    Hicks, David G.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (06) : 1677 - 1688
  • [28] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
    Mano, Max S.
    FUTURE ONCOLOGY, 2020, 16 (32) : 2595 - 2609
  • [29] Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    Sugimoto, Riho
    Sakaguchi, Kouichi
    Kotani, Tatsuya
    Hukuda, Kenichirou
    Kawakami, Sadao
    Hujiwara, Ikuya
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
12345